First study of neoadjuvant use of PARP inhibitor shows promise for early-stage, BRCA+ breast cancer patients
Credit: MD Anderson Cancer Center CHICAGO - In a small Phase II study of early-stage breast cancer patients with BRCA1/2 mutations, researchers at The University...